Evommune filed confidentially to go public to raise capital for two mid‑stage programs: EVO756, an oral MRGPRX2 antagonist for chronic spontaneous urticaria and atopic dermatitis, and EVO301, an IL‑18 neutralizing fusion protein. The company reported encouraging Phase II signals for EVO756 and plans Phase 2/3 advancement contingent on financing. Evommune’s IPO move signals renewed biotech market access for clinical‑stage autoimmune companies seeking growth capital. The proceeds are slated to support pivotal studies and potential label expansions into related mast‑cell and inflammatory diseases.